| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Thrombophilia is a condition that predisposes to a higher incidence of
venous thromboembolisms (VTE), some also in atypical sites. Direct oral
anticoagulants (DOACs) have proven to be effective in the treatment of
deep vein thrombosis (DVT). However, their use can be sometimes
challenging in particular settings of patients such as those with major
thrombophilia - antithrombin, protein C and protein S deficiency,
homozygous mutation of Factor V Leiden, homozygous mutation of Factor
II G20210A, combined heterozygous mutation of factor V Leiden and
Factor II G20210A – carrying a high thrombotic risk.
|Table1. Patients’ characteristics.|
|Table 2. Major thrombophilia groups and DOACs administered.|
|Table 3. Results.|